October 2, 2024

Josh Mandel-Brehm
Chief Executive Officer
CAMP4 Therapeutics Corp
One Kendall Square
Building 1400 West, 3rd Floor
Cambridge, MA 02139

       Re: CAMP4 Therapeutics Corp
           Amendment No. 1 to Registration Statement on Form S-1
           Filed September 26, 2024
           File No. 333-282241
Dear Josh Mandel-Brehm:

     We have reviewed your amended registration statement and have the
following
comments.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Prospectus Summary
CMP-CPS-001: Potential treatment for urea cycle disorders, page 5

1.     We note your disclosure on pages 5 and 130 that as of September 2024,
the Safety
       Review Committee of your Phase 1 clinical trial of CMP-CPS-001 has
reviewed all
       reported interim safety data, including treatment emergent adverse
events from SAD
       cohorts 1 through 3, and that to date, "no safety trends of concern have
been observed,
       and CMP-CPS-001 has been well tolerated." Please tell us whether any
treatment related
       serious adverse events ("SAEs") occurred in your clinical trial, and if
so, describe each
       SAE and quantify the number of occurrences. Alternatively, if true,
affirmatively state
       that no SAEs occurred.
 October 2, 2024
Page 2

       Please contact Gary Newberry at 202-551-3761 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Lauren Hamill at 303-844-1008 or Joe McCann at 202-551-6262 with any
other
questions.



                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Life
Sciences
cc:   Thomas Danielski